Dare Bioscience

Dare Bioscience Altman Z-Score

The Altman Z-Score of Dare Bioscience (DARE) as of Oct 26, 2026 is -9.10. In the previous year, Altman Z-Score was -14.21 — a change of -35.93% (higher).

Altman Z-Score

-9.10

YoY

-35.93%

Last updated:

Altman Z-Score of Dare Bioscience is 2025 -9.10 . Altman Z-Score of Dare Bioscience was 2024 -14.21 . It decreases by -35.93% higher compared to the previous year.

The Dare Bioscience Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2018
-2.17 USD
Jan 1, 2019
-13.05 USD
Jan 1, 2020
-23.94 USD
Jan 1, 2021
-4.24 USD
Jan 1, 2022
-6.30 USD
Jan 1, 2023
-15.51 USD
Jan 1, 2024
-14.21 USD
Jan 1, 2025
-9.10 USD
The Dare Bioscience Altman Z-Score history
YEARAltman Z-ScoreYoY
-9.10-35.93%
-14.21-8.37%
-15.51+146.10%
-6.30+48.60%
-4.24-82.29%
-23.94+83.45%
-13.05+500.35%
-2.17-128.09%
7.74-175.60%
-10.23+150.94%
-4.08+33.12%
-3.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Altman Z-Score of Dare Bioscience is -9.10 in 2025.

On Eulerpool you can find the complete historical development of Altman Z-Score Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Dare Bioscience

All Key Metrics — Dare Bioscience